| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:(R)-Fadrozole CAS:102676-87-9 Purity:98%+ HPLC Package:10mg,500mg,1g,2g,5g,10mg,more
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:(R)-Fadrozole CAS:102676-87-9 Package:25mg/RMB 10800
|
| Company Name: |
Hubei YoungXin Pharmaceutical Tech Co.,Ltd.
|
| Tel: |
0714-3999001 17771081808 |
| Email: |
2654977911@qq.com |
| Products Intro: |
Product Name:Fadrozole Impurity 1 CAS:102676-87-9 Purity:99% HPLC Package:10mg、25mg、50mg、100mg
|
Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- manufacturers
- (R)-Fadrozole
-
- $1543.00
-
2026-05-11
- CAS:102676-87-9
- Purity:
- Supply Ability: 10g
|
| | Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- Basic information |
| Product Name: | Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- | | Synonyms: | Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]-;(R)-CGS 16949A free base;(R)-Fadrozole;(R) Fadrozole,(R)Fadrozole;(R)-4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile;Fadrozole Impurity 1 | | CAS: | 102676-87-9 | | MF: | C14H13N3 | | MW: | 223.27 | | EINECS: | | | Product Categories: | | | Mol File: | 102676-87-9.mol | ![Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- Structure](CAS/20210111/GIF/102676-87-9.gif) |
| | Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- Chemical Properties |
| Boiling point | 481.7±38.0 °C(Predicted) | | density | 1.20±0.1 g/cm3(Predicted) | | form | Solid | | pka | 7.16±0.40(Predicted) | | color | Light yellow to yellow |
| | Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- Usage And Synthesis |
| Uses | Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor[1]. Dexfadrostat also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2]. | | in vivo | Dexfadrostat ((R)-fadrozole; 0.24 and 1.2 mg/kg; daily; oral) and (S)-fadrozole similarly decreases plasma aldosterone levels, whereas urinary aldosterone excretion rate was reduced only by S-fadrozole[2].
Dexfadrostat (0.24 and 1.2 mg/kg; daily; oral) effectively reverses preexistent left ventricular interstitial fibrosis by 50% (vs. 42% for canrenoate), S-fadrozole was devoid of an antifibrotic effect[2]. | Animal Model: | SHHF rats[2] | | Dosage: | 0.24 and 1.2 mg/kg | | Administration: | Daily; oral | | Result: | Decreased plasma aldosterone levels and reversed preexistent left ventricular interstitial fibrosis.
|
| | References | [1] Furet P, et al. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993;36(10):1393-1400. DOI:10.1021/jm00062a012 [2] Minnaard-Huiban M, et al. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. Endocrinology. 2008;149(1):28-31. DOI:10.1210/en.2007-0584 |
| | Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl]- Preparation Products And Raw materials |
|